xm:刁星星
xb:男
zc:研究员
xl:博士
dh:； **
cz:
dzyj:xxdiao@simm.ac.cn
grzy:https://www.linkedin.com/in/xingxing-diao-**
zjlb:研究员
zw:课题组长
txdz:上海浦东张江海科路501号1-705室 201203
grjj:刁星星，中国科学院上海药物研究所研究员、课题组长。

2014年于中国科学院上海药物研究所获得博士学位。博士毕业后，先在美国国立卫生研究院NIH/NIDA进行博士后研究，然后在美国XenoBiotic Laboratories和Celgene公司从事药物代谢工作，研究放射性同位素标记药物的代谢。2019年2月加入上海药物研究所，担任课题组长，主要从事放射性药物代谢及药动学研究。

前期系统研究了烷基侧链类药物的代谢途径，阐明了烷基侧链类药物丁苯酞人体肝毒性的代谢活化机理，并揭示了同分异构体代谢物在血脑屏障两侧浓度比值反转的机制。在NIH/NIDA建立了完整的新型毒品人肝细胞代谢平台，构建了新型毒品代谢研究策略，广泛用于司法鉴定。在美国新泽西州XenoBiotic Laboratories和Celgene，从CRO和新药研发企业不同的角度系统学习掌握了放射性同位素标记技术在药物代谢（DMPK）上的应用。

2012年至今，共发表学术论文33篇，其中通讯作者/第一作者21篇，包括DMPK领域著名杂志Drug Metabolism and Disposition，Clinical Chemistry，Clinical Pharmacology & Therapeutics等。总被引用超过994次（Google Scholar），H-因子：21。关于丁苯酞（我国脑血管领域第一个拥有自主知识产权的1.1类新药）的研究，被引用近200次。

教育经历：

2005.9-2009.6，武汉大学，药学，理学学士

2009.9-2014.7，中国科学院大学，药物分析，理学博士

yjfx:1、药物代谢、药物不良反应机理、新代谢途径、反常药动学、药物代谢新技术；

2、放射性药物代谢（低辐射能量同位素[¹⁴C]/[³H]标记技术在新药DMPK中的应用）；

3、大鼠[¹⁴C]实验（PK、物质平衡、组织分布、代谢物谱分析、代谢物鉴定等）；

4、人体[¹⁴C]试验（PK、物质平衡、B/P值、代谢物谱分析、代谢物鉴定等）；

5、In vitro放射性DMPK实验（肝细胞种属比较、肝细胞稳定性、代谢物鉴定等）；

6、人体MIST实验（鉴定人血浆中占药物相关物质10%以上的代谢物等）。

dblz:1.Zheng Y#, Zhang H#, Zhan Y, Bian Y, Ma Sheng, Gan H, Lai X, Liu Y, Gong Y, Liu X, Sun H, Li Y, Zhong D*, Miao L*, Diao X* (2020). Pharmacokinetics, Mass Balance, and Metabolism of [14C]Vicagrel, a Novel Irreversible P2Y12 Inhibitor in Humans. Acta Pharmacol Sin, Accepted

2.Pan L, Yang Y, Hui M, Wang S, Li C, Zhang H, Ding Y*, Fu L*, Diao X*, Zhong D* (2020). Sulfation predominates the pharmacokinetics, metabolism, and excretion of forsythin in humans: major enzymes and transporters identified. Acta Pharmacol Sin, In press

3.Liu X, Guo Z, Chen Z, Zhang Y, Zhou J, Jiang Y, Zhao Q, Diao X*, Zhong D* (2020). Alflutinib (AST2818), primarily metabolized by CYP3A4, is a potent CYP3A4 inducer. Acta Pharmacol Sin, 1-11

4.Pan L, Guo S, Chen X, Jiang X, Shen J, Diao X*, Wang Z*, Zhong D* (2019). Characterization of TPN171 metabolism in humans via ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal, 172: 302-310

5.Diao X, Huestis MA (2019). New Synthetic Cannabinoids Metabolism and Strategies to Best Identify Optimal Marker Metabolites. Frontiers in Chemistry, 7: 109. Invited Review

6.Diao X, Carlier J, Zhu M, Huestis MA (2018). Metabolism of the new synthetic cannabinoid EG-018 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicol, 36:304-312

7.Carlier J#, Diao X#, Huestis MA (2018). Synthetic cannabinoid BB-22 (QUCHIC): Human hepatocytes metabolism with liquid chromatography-high-resolution mass spectrometry detection. J Pharm Biomed Anal, 157: 27-35

8.Diao X#, Carlier J#, Zhu M, Huestis MA (2017). Human hepatocyte metabolism of novel synthetic cannabinoids MN-18 and its 5-fluoro analog 5F-MN-18. Clin Chem, 63: 1753-1763

9.Diao X#, Carlier J#, Scheidweiler KB, Huestis MA (2017). In vitro metabolism of new synthetic cannabinoid SDB-006 in human hepatocytes by high-resolution mass spectrometry. Forensic Toxicol, 35: 252-262

10.Diao X, Huestis MA (2017). Approaches, challenges and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites. Clin Pharmacol Ther, 101: 239-253. Invited Review

11.Carlier J#, Diao X#, Sempio C, Baumann MH, Huestis MA (2017) Identification of new synthetic cannabinoid ADB-CHMINACA (MAB-CHMINACA) metabolites in human hepatocytes. AAPS J, 19: 568-577

12.Diao X, Carlier J, Zhu M, Pang S, Kronstrand R, Scheidweiler KB, Huestis MA (2017). In vitro and in vivo human metabolism of a new synthetic cannabinoid NM-2201 (CBL-2201). Forensic Toxicol, 35: 20-32

13.Diao X, Scheidweiler KB, Wohlfarth A, Zhu M, Pang S, Huestis MA (2016). Strategies to distinguish new synthetic cannabinoid FUBIMINA (BIM-2201) intake from its isomer THJ-2201: metabolism of FUBIMINA in human hepatocytes. Forensic Toxicol, 34: 256-267

14.Diao X, Scheidweiler KB, Wohlfarth A, Pang S, Kronstrand R, Huestis MA (2016). In vitro and in vivo human metabolism of synthetic cannabinoids FDU-PB-22 and FUB-PB-22. AAPS J, 18: 455-464

15.Diao X, Wohlfarth A, Pang S, Scheidweiler KB, Huestis MA (2016). High-resolution mass spectrometry for characterizing the metabolism of synthetic cannabinoids THJ-018 and its 5-fluoro analog THJ-2201 after incubation in human hepatocytes. Clin Chem, 62: 157-169

16.Diao X, Zhong K, Li X, Zhong D, Chen X (2015). Isomer-selective distribution of 3-n-butylphthalide (NBP) hydroxylated metabolites, 3-OH-NBP and 10-OH-NBP, across the rat blood-brain barrier. Acta Pharmacol Sin, 36: 1520-1527

17.Diao X, Pang X, Xie C, Guo Z, Zhong D, Chen X (2014). Bioactivation of 3-n-butylphthalide via the sulfation of its major metabolite 3-hydroxy-NBP: mediated mainly by sulfotransferase1A1. Drug Metab Dispos, 42: 774-781

18.Diao X, Chen X (2014). The role of aldehyde oxidase in drug metabolism. Journal of Baoji University of Arts and Sciences (Natural Science) (in Chinese), 34: 26-38. Invited Review

19.Diao X, Ma Z, Wang H, Zhong D, Zhang Y, Jin J, Fan Y, Chen X (2013). Simultaneous quantitation of 3-n-butylphthalide (NBP) and its four major metabolites in human plasma by LC–MS/MS using deuterated internal standards. J Pharm Biomed Anal, 78: 19-26

20.Diao X, Ma Z, Lei P, Zhong D, Zhang Y, Chen X (2013). Enantioselective determination of 3-n-butylphthalide (NBP) in human plasma by liquid chromatography on a teicoplanin-based chiral column coupled with tandem mass spectrometry. J Chromatogr B, 939: 67-72

21.Diao X, Deng P, Xie C, Li X, Zhong D, Zhang Y, Chen X (2013). Metabolism and pharmacokinetics of 3-n-butylphthalide (NBP) in humans: the role of cytochrome P450s and alcohol dehydrogenase in biotransformation. Drug Metab Dispos, 41: 430-444

jyjl:2005.9-2009.武汉大学，药学，理学学士